Pickering M C, Warren J, Rose K L, Carlucci F, Wang Y, Walport M J, Cook H T, Botto M
Rheumatology Section and Department of Histopathology, Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom.
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9649-54. doi: 10.1073/pnas.0601094103. Epub 2006 Jun 12.
Membranoproliferative glomerulonephritis (MPGN) type II (dense deposit disease) is an inflammatory renal disease characterized by electron-dense deposits and complement C3 on the glomerular basement membrane. There is no effective therapy. We investigated the role of C5 activation in a model of MPGN that develops spontaneously in complement factor H-deficient mice (Cfh(-/-)). At 12 months there was a significant reduction in mortality, glomerular cellularity, neutrophil numbers, and serum creatinine levels in Cfh(-/-) mice deficient in C5. Excessive glomerular neutrophil numbers, frequently seen in patients with MPGN during disease flares, were also observed in Cfh(-/-) mice after the administration of an antiglomerular basement membrane antibody. This exaggerated injurious phenotype was absent in Cfh(-/-) mice deficient in C5 but not in Cfh(-/-) mice deficient in C6, indicating a key role for C5 activation in the induction of renal lesions. Importantly, the renal injury was completely reversed in Cfh(-/-) mice pretreated with an anti-murine C5 antibody. These results demonstrate an important role for C5 in both spontaneous MPGN and experimentally induced nephritis in factor H-deficient mice and provide preliminary evidence that C5 inhibition therapy might be useful in human MPGN type II.
II型膜增生性肾小球肾炎(MPGN,致密物沉积病)是一种炎症性肾脏疾病,其特征为肾小球基底膜上存在电子致密沉积物和补体C3。目前尚无有效治疗方法。我们在补体因子H缺陷小鼠(Cfh(-/-))自发发生的MPGN模型中研究了C5激活的作用。12个月时,C5缺陷的Cfh(-/-)小鼠的死亡率、肾小球细胞数量、中性粒细胞数量和血清肌酐水平均显著降低。在给予抗肾小球基底膜抗体后,Cfh(-/-)小鼠中也观察到了MPGN患者疾病发作时常见的肾小球中性粒细胞数量过多的情况。这种过度的损伤表型在C5缺陷的Cfh(-/-)小鼠中不存在,但在C6缺陷的Cfh(-/-)小鼠中存在,表明C5激活在肾损伤诱导中起关键作用。重要的是,用抗小鼠C5抗体预处理的Cfh(-/-)小鼠的肾损伤完全逆转。这些结果证明了C5在因子H缺陷小鼠的自发性MPGN和实验性诱导性肾炎中均起重要作用,并提供了初步证据表明C5抑制疗法可能对人类II型MPGN有用。